DXM-[illegible]?

Recovery Kernel [illegible]

DXM · [illegible] · [illegible] · [illegible] · [illegible] · [illegible] · [illegible] · [illegible] · [illegible]

⚠ [illegible] - [illegible] | [illegible]: **112** [illegible] **14416 or 1800-89-14416** [illegible]

DXM + SSRI [illegible] MAOI = [illegible]. [illegible] [illegible].

DAYQUIL, NYQUIL, TRIPLE C [illegible] [illegible].

CYP2D6 [illegible] (DXM) [illegible].

[illegible]

Recovery Kernel Compendium [illegible] [illegible]. [illegible], [illegible] [illegible] [illegible] [illegible] систематиз[illegible] [illegible].

[illegible], OTC [illegible]: '[illegible].' CYP2D6 фарма[illegible] [illegible] [illegible]. [illegible] [illegible], [illegible] [illegible]. [illegible] OTC [illegible] [illegible] DXM [illegible]: [illegible] CYP2D6 [illegible] [illegible] DXM [illegible].

[illegible], [illegible]-Glutathione [illegible]: [illegible], [illegible] (

) □□□□□□□□□□□□□ □□□□□□□□. □□ DXM □□□□□□□□ □□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□. □□□□□□□□□ □□□□□□, □□□□□□□□□□□□□□□ □□□□□ □□□□□□□□□ □□□□ □□□□□□□□□□□□□□□□□ □□□□□□□□□□□. NyQuil □□□□□□□□□□□ DayQuil □□□□□□□□□□ □□□□□□□ DXM-□□□□□ □□□□□□□□□□□ □□□□□□□ □□□□□□□□ □□□□□□□□ □□□□□□□□□ □□□□□□□ □□□□ □□□□ □□□□□□□□□□□ □□□□□□□□ □□□□□ □□□□□□□□□□□ □□□□□□□□□□□□□□.

□□□□□□□□□□□□□, □□□□□□□□□□□□□□□□ NMDA □□□□□□□□□□: DXM-□□□□□ □□□□□□□□□ □□□□□□□□□ □□□□□□□□□ NMDA □□□□□□□□□□ □нта□□□□□□ □□□□ □□□□□□□□□□□□□□□□□□□□□ - □□□□□□□□□□ □□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□ □□□□□□□□□□ □□□□ □□□□□□□□□□□□□□□. □ □□□□□□□□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□, □□□□ □□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□, □□□□ □□□□ □□□□□□□□□□□□□□□, □□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□ □□□□□□ □□□□□□□□□ - □□□□□□ $8 □□□□□□□□□□□□□, □□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□

□□□□□□□ 0 — □□□□□□□□□ □□□□□□□: □□□□□□□□□ □□□□□□□□□□□□□

DXM □□□□□□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□□□ □□□□□□□ DXM □□□□□ - □□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□.

0.1 — □□□□□□□□□ □□□□□□□□: □□□□□□□□□□ □□□□□□□□□□□□ □□□□□□□

□□□□□□□□□□□□ — OTC □□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□ — □□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□□□□□□

DXM □□□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□□. DXM □□□□□□□□ □□□□□□ □□□□□□□□□□□□□□□ □□□□□□□ □□□□□□□□□□□□□□□□, DXM-□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□ □□□□□□□□□□ □□□□□□ □□□□□□□□□□□□□□ □□□□□□ □□□□□□□□□□□ □□□□□ □□□□□ □□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□. □ □□□□□□□ □□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□□□□□□□□

		в □□□□□□□□□□□□□□□, □□□□□□□□□□□□□□□, □□□□□□□□□□, □□□□□□□□□□ □□□□□□□□□. □□□□□□□□□□ □□ □□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□.	□□□□□□□□□□□□□□□□□□ □□□□□□. □□□□ □□□□□□□□ □□□□□□□□□□ □□□□□□□□ □□□□□□□□□□.
□□□□□□□□□□□□ ()	□□□□□□□□□□□□□ □□□□□, □□□□□□□ □□□□□□□□□□□	□□□□□ □□□□□□ □□□□□□□□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□, □□□□□□□ □□□□□□□ □□□□□□□□□. □□□□ □□□□□□□□□ □□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□, □□□□□□□ □□□□□□□□□□□ DXM □□□□□□□ □□□□□ □□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□ □ □□□□□□□□□□□□□□□□□□ □□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□ □□□□□□□□□.	□□□□□□□□□ □□□□□□□□□□□□□□ □□□□□□□□ □□□□□□□ □□□□□□□□□□□□□ □□□□□□□□□□ □□□□□□□. □□□□□□□. □□□□□□ □□□□□□□□□□□□ □□□□ □□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□, □□□□□□ □□□□□□□ □□□□ (GI) □□□□□□□□□□□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□ □□□□□□□□□□ □□□□□□□ □□□□ □□□□□□□□□□□□□□□□□□□□

	HBr □□□ □□□□□□□□□□□□□□, □□□□□□□□□ 12-□□	□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□, □□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□. □□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□□□□ □□□ □□□□□□□□□□□ □□□□□ □□□□□□□□.	□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□. □□□□□□□ □□□ □□□□□ □□□□□□□□□ □□□□□□□□□□□, □□□□□□□□□□□□□□□.	

⚠ □□□□□□□□□□ □□□□ & □□□□□□ (□□□□□□□ □□) □□□□□□□ □□□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□ **DXM** □□□□□□□□□□□□□□□. □□□□□□□□□□□□□□□□ □□□□□□□□□□□□□ □□□□□□□□□ □□□□□□□□ □□□□□□□□□, **DXM** □□□□□. □□□□□□□□ **DXM** □□□□□□□□□□□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□ □□ □□□□□□□□□□□□□□□□.

0.2 — □□□□□□□ □□□□□□□□□: □□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□□□□□□□□□

⚠ **DXM** □□□□□□□□□□ □□□□□□□□□. □□□□□□□□□□ □□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□□□. □□□ **DXM** □□□□□□□□□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□, □□□ □□□□□□□□□□□□□ □□□□□□ □□□□□□□□□□□□□□□□.

DXM □□□ □□□□□□□□ □□□□□□□□□□□ □□□□ - □□□ SERT □□□□□□□□□ □□□□□□□□□□□□, SSRI-□□ □□□□□□□□□ □□□□□□□□□□ □□□□ □□□□□□□□□□□□□□□□□□. □□□□□□□□ □□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□, □□□ □□□□□□□□□□ □□□□□□□□ □□□□□□□□□ □□□□□□□□□:

- SSRIs (Prozac/fluoxetine, Zoloft/sertraline, Lexapro/escitalopram, Celexa/citalopram, Paxil/paroxetine): □□□□□□□□□□ SERT □□□□□□□□□ — DXM-□□□□□ □□□□□□□□□□□□□□□□□□ = □□□□□□□□ □□□□□□□□□ □□□□□□□. □□□□□□□□□□□□□□□□ Paroxetine □□□ □□□□□□□□ CYP2D6 □□□□□□□□□□□□□□□□, □□□□□□□ □□□□ DXM □□□□□ □□□□□□□□□□□□□□ □□□□□□□□□□, □□□□ DXM □□□□□□□□ □□□□□ □□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□ □□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□□.
- □□□□□□□□□□□ (□□□□□□□□□/□□□□□□□□□□□□□□□, □□□□□□□□□□□/□□□□□□□□□□□□□□□□□): □□□□□□□□□□, □□□□□□□□□□□□□ □□□□□□□□□□ — □□□□□□□□□□□-□□□□□ □□□□□□□□□□□ = □□□□□□□ □□□□□□□□□□ □□□□□□□□□ □□□□□□□.
- MAOIs (□□□□□□□□, □□□□□□□□□□□□□□□□□□□□, □□□□□□□□□□, □□□□□□□ □□□□□□□□□□ □□□□□□□ □□□□□□ □□□□□□□□, /□□□□□□□□□□): □□□□□□□□ □□□□□□□□□□ □□□□□□□□□□ — DXM-□□□□□ □□□□□□□□□□□□□□□□□□ = □□□□□□□□□□, □□□□□□□□ □□□□□□□□ □□□□□□□□□. □ □□□□□□□□ □□□□□□□ □□□□□□□□□□□□□□□□□□.
- □□□□□□□□□: □□□□□□□□ □□□□□ □□□□□□□□□□ — DXM-□□□□□ □□□□□□□□□□ = □□□□□□□ □□□□□□□□ □□□□□□□□□ □□□□□□□.

- [illegible] (MAOI [illegible]): [illegible]

[illegible]: [illegible], [illegible], [illegible], [illegible], [illegible] **Pupil-**[illegible], [illegible] [illegible] [illegible] [illegible] **(**[illegible]**),** [illegible], [illegible], [illegible]. [illegible] [illegible]. **112-**[illegible].

CYP2D6 [illegible] [illegible]: **CYP2D6** [illegible] [illegible] [illegible], [illegible] **DXM** [illegible] [illegible] **SERT-**[illegible] [illegible] [illegible] **— DXM** [illegible] [illegible] [illegible] [illegible] **SERT-**[illegible]. [illegible] **CYP2D6** [illegible] [illegible]: **DXM +** [illegible] [illegible] **(contraindication).**

0.3 — [illegible]

[illegible]	[illegible]	[illegible]
[illegible] [illegible] / [illegible] (MAOI)	[illegible], [illegible], [illegible], [illegible], [illegible] [illegible], [illegible] [illegible].	[illegible] [illegible]. 112-[illegible]. [illegible] [illegible] (MAOI, [illegible], [illegible]). [illegible], [illegible]. [illegible] [illegible] [illegible] [illegible]. EMS [illegible]: 'DXM — — [illegible].'
[illegible] (MAOI [illegible])	[illegible] [illegible] [illegible], [illegible] الرغم [illegible], [illegible], [illegible], [illegible]. [illegible] [illegible] DXM [illegible], [illegible] [illegible] [illegible] [illegible] [illegible].	[illegible] 112 [illegible]. [illegible] [illegible]. [illegible], [illegible], [illegible] [illegible]. [illegible]. [illegible] [illegible] DXM [illegible] [illegible] [illegible] [illegible] [illegible].

[illegible] [illegible] (DXM) [illegible] [illegible]	[illegible] [illegible] [illegible] [illegible] [illegible]. DXM-[illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] - [illegible] [illegible] [illegible].	Naloxone [illegible] [illegible] (DXM-[illegible] [illegible] [illegible] [illegible] [illegible]. 112. [illegible] [illegible] [illegible] [illegible]. [illegible] [illegible] [illegible].
[illegible]	[illegible] (DXM) [illegible] [illegible], [illegible] [illegible] [illegible] [illegible].	[illegible] [illegible]. [illegible]. [illegible] [illegible]. [illegible] (EMS) [illegible] [illegible].

Глава 1 — Механизмы взаимодействия декстрометорфана с антидепрессантами

Ко времени написания — доказательная база сформирована, клинические рекомендации, основанные на ней, сложились. Ниже изложено то, что известно.

DXM фармакологически неоднороден. Его свойства определяются не только собственной молекулой, но и тем, что организм делает с ней после приема. Ключевой фермент — CYP2D6, и именно его генетическая вариабельность — причина большинства непредсказуемых реакций. В этой главе разобраны механизмы, по которым DXM-содержащие препараты взаимодействуют с антидепрессантами, и почему одни сочетания опасны, а другие — нет.

1.1 — Какие антидепрессанты представляют риск

Антидепрессант / класс	Взаимодействие с DXM	Клинические последствия
NMDA-антагонисты (кетамин, эсketамин)	DXM блокирует CYP2D6 и сам является NMDA-антагонистом — оба механизма усиливают эффект	Усиление диссоциации, седации, риск передозировки. Сочетание не рекомендуется.
Ингибиторы МАО (фенелзин, транилципромин, селегилин, моклобемид)	DXM может вызывать серотониновый синдром; ингибиторы МАО повышают уровень серотонина	Серотониновый синдром: гипертермия, ригидность, клонус, нарушение сознания. Потенциально летальное осложнение.
СИОЗС (флуоксетин, сертралин, пароксетин, циталопрам, эсциталопрам)	Ингибируют CYP2D6, снижают метаболизм DXM	Повышение концентрации DXM, усиление седации и диссоциации. Риск серотонинового синдрома при высоких дозах.
Трициклические антидепрессанты (амитриптилин, имипрамин, кломипрамин, нортриптилин)	Ингибируют CYP2D6; сами обладают антихолинергическим действием	Усиление седации, спутанности, задержки мочи. Риск серотонинового синдрома.
Бупропион	Ингибирует CYP2D6	Повышение концентрации DXM, усиление эффектов.
Миртазапин, тразодон	Слабое влияние на CYP2D6	Клинически значимое взаимодействие маловероятно, но седация может суммироваться.

	□□□□□□□□□□□□□□ (dissociative) □□□□□□□□□□□ □□□□□□□□□□□□□□ □□□□□□□□□□□□□□ □□□□□□□□□□ (psychedelic) □□□□□□□□□ □□□□□□□□□□ DXM □□□□□□□ □□□□□□□□□□.	
□□□□□□□□□□ □□□□□□□□□□□□□□□□ □ (SERT □□□□□□□□□□)	DXM □□ □□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□□ - □□□□□□□ □□□□□□□□□□ SSRI-□□□□□□□□□ □□□□□□□□□ □□□□ □□□□□□□□□, □□□□□□□ □□□□□□□□□ □□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□ □□□□ □□□□□□□□□□□□□. SERT □□□□□ □□□□□□□ □□□□□□□□□□ DXM-□□□□□ □□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□.	□□□□□□□□ □□□□□□□□□ □□□□□□□□□ □ □□□□□□□□□ MDMA □□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□ - □□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□ 5-HTP □□□□□□□□ □□□□□□□□□, □□□□□□□ SERT □□□□□ □□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□□□□□□□ 5-HTP □□□□□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□ □□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□. □□□□□□ DXM □□□□□□□□□□□□□ □□□□□ 5-HTP □□□□□□□□□□□□□□□□□□□ □□□□□□□ 3–5 □□□□□□ □□□□□□□□□□□□□□□□.
□□-□□□□□□□□□□ □□□□□□□□□□□□□□□ (□□□□□□□□□□ □□□□□□□□□)	DXM □□ □□□□□□□□□ □□□□□-□□□□□□□□ □□□□□□□□□□ □□□□□□ — □□□□□□□ □□□□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□ □□□ □□□□□ □□□□□□□ (4-□□ □□□□□) □□□□□□□□□ □□□□□□□□□□□□□, □□□ □□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□ □□□□□ □□□□□□□□□□ □□□□□□□□□□ Naloxone □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□.	□□□□□□□□□□□□□□□□□□ □□□□□□□□□□, □□□□□□□□□□ □□□□□ □□□□□ □□□□□□□□. □□□□□□ □□□□□□□□□□ □□□□□□□□□□ (1000mg+), □□□□□□□□□□ □□□□□ □□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□ □□□□□□□ □□□□□□□□□. DLPA (□□□□□□□□□□□□□□ □□□□□□□□□□□□) □□□□□□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□, □□□□□□ □□□□ □□□□□□□□□□-□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ DXM □□□□□□□□□□□□□ □□□□ □□□□□□□□□ □□□□□□□□□□□□□.

1.2 — □□□□□□□2□□6 □□□□□□□□□□□: □□□□ □□□□□□□□□□□ □□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□

□□ □□□□□□□□□□ — □□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□□□ □□□□□□□□□ □□ **OTC** □□□□□□□□□

□□□□□□□□□□□□□□□ CYP2D6 □□□□□□ □□□□□□□□□□□□□□□□□□□□: '□□□□□ □□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□

		(□□□□□□□□□□□□□□□□, □□□□□□□□□□□□□□□□□□, □□□□□□□□□□□□□□□□) □□□□□□□-□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□ □□□□□ □□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□, □□□□ DXM □□□□□□□, □□□□□□□□□□□□ □□□□□□□□ □□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□.
□□□□□□ □□□□□□□□□□□□□□ CYP2D6 □□□□□□□□□□□□□□□□□	□□□□□□□□□□□□□□□□□□ (□□□□□□□□□□) □□ □□□□□□□□□□□□□□□□□ (□□□□□□□□□) □□ □□□□□□□ SSRI-□□□□□□ □□□□□□□□ □□□□□□□□ CYP2D6 □□□□□□□□□□□□□□□□□□□□□□□□. □ □□□□□□□□□□ □□□□□□□□□□□□□□□ DXM □□□□□□□□□□□□□ □□□□ □□□□□□□ CYP2D6 □□□□□□□□□□□□□□ □□□□□□□□ □□□□ □□□□□ □□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□ — DXM □□□□□□□□□□□□□□□□□□, □□□□□□□□ □□□□□□□□□ □□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□□□□□, □□□□□□□ SSRI □□□□□□□□□□□ SERT □□□□□□□□□□□□ □□□□□ □□□□□□□□□□□□□.	DXM + Prozac □□□□□□□□□□□ DXM + Paxil □□□□□□□ OTC □□□□□□□□□□□□□ □□□□□□□□ □□□□□□□ □□□□□□□□□□□□□ □□□□oton □□□□□□□□□ □□□□□□□□ □□□□□□□□□□□□□ □□□□□□□□. □ □□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□. □□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□.

1.3 — □□□□ □□□□□□□□: □□□□-□□ □□□□□□□□□□□□

□□ □□□□□□□□□□ — □□□□□□□□□□ □□□□□ □□□□□□□□□□ □□□□□□ □□□□□□□□□□ □□□□□□□□□□

DXM-□□□□ □□□□□□□□□□□□□□□□□□□□ '□□□□□□□□' □□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□ □□□□□□□□□□□□□□□□□□, □□□□□□□□ □□□□□□ DXM □□□ □□□□□□□□ □□□□□□□□□□□□□□□ □□□ - □□□□□□□□□□□□ □□□□□□□ □□□□□□□□-□□□□□ DXM FAQ □□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□□ □□□ □□□□□□□. DXM-□□□□□ □□□□□ □□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□□□□□□□ □□□□ □□□□□□□□□□□□□□□□□. □ □□□□□□□□□□□□□□ □□□□□□□□□ □□□□□ □□□□□□□ □□□□□□□□□□□□□□□: □□□□□□□□ □□□□ □□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□, □□□□ □□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□ □□□□□□□ □□ □□□□□□□□□□□□□□□□ □□□□□□□.

□□□□□□□□□	□□□□□□ □□□□□	□□□□□□□□□ □□□□□□□	□□□□□□□ **фарма**□□□□□□□□□□□□□□ □□□□□□□□□
□□□□□□□□□ □□□□□□	100–200□□□□□□□□□ □□□□	□□□□□□ □□□□□□□□□, □□□□□□□□□, □□□□□□□□□□ □□□□□□□□ □□□□□□□, □□□□□□ □□□□□□ □□□□□□□□□□□□□□□□□□□□. □□ □□□□□□□□□□□□□□□□□□□□ □□□□ □□□□□□ □□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□□□□□.	□□□□□□□□□□□□□ □□□□□□-1 □□□□□□□□□, □□□□□□ SERT □□□□□□□□□□□. □ □□□□□□ NMDA □□□□□□□ □□□□□□□□□. □□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□ DXM □□□□□□□□□□□ □□□□□ □□□□□□□□□□□□□□.
□□□□□□□□□□□□	200–	□□□□□□□ □□□□□□, □□□□□□□□□□□□□	□□□□□□□ CYP2D6 □□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□

[illegible]	400[illegible] [illegible]	[illegible], [illegible] [illegible], [illegible] [illegible] [illegible], [illegible] [illegible] [illegible]. [illegible].	[illegible] NMDA [illegible] [illegible]. [illegible] [illegible] [illegible]. [illegible] [illegible] [illegible].
[illegible] [illegible]	400–700[illegible] [illegible]	[illegible] [illegible] (dissociation), [illegible] [illegible] [illegible] (out-of-body experience), [illegible] [illegible] [illegible], [illegible] [illegible], '[illegible]-[illegible]' [illegible] '[illegible]-[illegible]' [illegible]. [illegible] [illegible] — [illegible] [illegible] [illegible].	DMN [illegible] [illegible] [illegible] [illegible]. [illegible]-1 [illegible]. [illegible], [illegible] [illegible] [illegible] — [illegible] DXM-[illegible] [illegible]- [illegible] фарма[illegible] [illegible].
[illegible] [illegible]	700–1500mg+	[illegible] [illegible] [illegible] [illegible] [illegible]. [illegible] [illegible]. [illegible] [illegible]. [illegible] [illegible] [illegible]. [illegible], [illegible] [illegible]. [illegible] [illegible].	[illegible]; [illegible] [illegible] [illegible] [illegible] [illegible]; [illegible] [illegible] [illegible]. [illegible] [illegible].

1.4 — [illegible] [illegible] [illegible]: [illegible] [illegible]

[illegible] — [illegible] [illegible]. [illegible] [illegible], [illegible] [illegible].

DXM-[illegible] [illegible]-[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

□□□□□□□□□□ □□□□□□□□	□□□□□□□□□□□. □□-□□□□□□□□□ DXM □□□□□ DMN □□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□□□□□□: □□□□□□-□□□□□□ □□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□.	□□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□. □□□□□□□□/□□□□□□□□□/NSDR □□□□□□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□.
□□□□□□□□ □□□□□□□□□□□□□ - □□□□□□□□□□□□ □□□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□□□□ □□□□□□□□	DXM-□□□□□ □□□□□□-1 □□□□□□□□□, □□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□ □□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□ □□□□□□□□□. □□□□□□□□□□□, □□□□□□□□ □□□□□□□□, □□□□□□□□□□□□□ □□□□□□□□ □□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□ - □□□□ □□□□□□□□ □□□□□□□□ □□□□□□□□□□□□ □□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□.	□□□□□□□□ □□□□□□□□□□□□□□□□ (5-HTP, □□□□□□□□□□□□). □□□□□□□□ □□□□□□□□ □□□□□□. □□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□

[illegible]	[illegible], [illegible] [illegible] [illegible] [illegible] - [illegible], [illegible] [illegible] (Reddit, [illegible]). [illegible] [illegible] [illegible].	[illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible] - [illegible] [illegible].

1.5 — [illegible] [illegible] [illegible] [illegible]

[illegible] — [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

DXM [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible] 2 — [illegible] [illegible] [illegible]

DXM-[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] фарма[illegible] [illegible] [illegible]. CYP2D6 [illegible] [illegible] [illegible] — [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

			□□□□□□□□□ □□□□□□□□□□□.
HTR2A	5-HT2A □□□□□□□□ □ □□□□□□□□□□ — □□□□□□□□□□□

□□□□□□□□□□□□□□□□□□	□□□□□□□□□□□□□□□□	□□□□□□□□□□□□□ (rs28363170)	□□□□□□□□□□□□□ DXM □□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□□ □□□□□□□□□ □□□□□□□□ □□□□□□□□□□□□□□ □□ ADHD □□□□□□. DXM-□□□□□ □□□□□□□-□□□□□□□□□□□ □□□□□□□□□□ ADHD □□□□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□□□□□□. ADHD □□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□□□□□□□ □□□□ □□□□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□.

□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□□□□□□□□□

- □□□□□□□□□□□□□□□□□□□□□□□□ DXM □□□□□□□□□□□□□□□□□□□□□□□□ → □□□□□□□ CYP2D6 □□□□□□□ — DXM □□□□□□□□□□□□□□□□□□□□□□□□□□□□□CYP2D6 □□□□□□□□SSRI□□□□□□□□□□□□□□□□□□□

[illegible] 3 — [illegible]: [illegible] [illegible] [illegible]

[illegible] — [illegible], [illegible] — [illegible] [illegible]. [illegible].

DXM [illegible] [illegible] [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] — NMDA [illegible], [illegible] [illegible] [illegible], HPPD [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible].

[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [

	□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□ DXM □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□. DXM □□□□□□□ □□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□, □□□□□□□□ □□□□□□□□, □□□□□□□□□□□□ □□□□□□□ □□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□ □□□□ □□□□□□□□□ □□□□□□□□□□ □□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□ '□□□□ □□□□□□ □□□□ □□□□□□□□ □□□□□□□' □□□□□ □□□□□□□ □□□□□□□□□□□□ □□□□□□.	□□□□□□□□□□□□□□ □□□□□□ □□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□, □□□□□□□ □□□□□□□□ NMDA □□□□□□□□□ □□□□□□□□□□, □□□□□□□□ □□□□□□□□□ □□□□□□□, □□□□□□□□□□□ □□□□□□□□ □□□□□□□□□□□ □□□□□□□ □□□□□□□□□□□□□□□□□□□□□□.' □ □□□□□□□□□□□ □□□□□□□□□□ □□□□□□ □□□□□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□ □□□□□□□□.
□□□□□□□□□□□□□□□□ □□□□□□□□	DXM □□□□□□□□□□ □□□□□□□□□□□□, □□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□□□□. □ □□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□ □□□□□□□ □□□□□□□□□□□□□, □□□□□□ □□□□□□□□□□□□, □□□□□□□□□□□□□□□□ □□□□□□□ □□□□□□□□□□□. □□ □□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□. □□□□ '□□□□□□ □□□□ □□□□□□□□' □□□□□□□□□□□ □□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□ □□□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□.	□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□ □□□□□□□□□□□□. □□□□□□ □□□□□□□□ □□□□□□□□□□□□ DXM □□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□□□□□□□. □□□□□□□□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□ (□□□□□□□ □□□□□□□□□, □□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□, □□□□□□□□□□ □□□□□□□□) □□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□.
□□□□□□□□□ □□□□□□□ □□□□□□□□□□	□□□□□□ DXM □□□□□□□□□□□□□ □□□□ □□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□. □□□□□□□□□□ DXM □□□□ □□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□, DXM-□□□□□ NyQuil □□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□ (□□□□□□□□□□□□□□□□□□ □□-□□□□□□□□□□) □□□□□□□□□□□□□ Triple C □□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□ (□□□□□□□□□□□□□□□□□□ □□□□□□□□□) □□□□□□□□□□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□□□□□□.	□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□. □□□□□□□□□ □□□□□□□□□□□□□□□□□□□□

□□□□□)	□□□□□

		[redacted]	[redacted].

[illegible] 4 — [illegible]

DXM [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]: NMDA [illegible] [illegible] [illegible] [illegible] (MDMA [illegible] [illegible], [illegible] [illegible] [illegible]), [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

			□□□□ □□□□□□ □□□□□□□□, □□□ □□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□□ □□□□□□□□ □□□□□□□□□□□□. DXM □□□□□□□□□□□□ NMDA □□□□□□□□□ □□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□. □□□□□ 1 □□□□□□□□□□.

4.2 — □□□□□□□□□□: □□□□□□□□□□□□ □□-□□□□□□□□□□□□□□□ □□□ □□□□□□□

⚠ □□□□□□□□□□ □□□□□□□□□□□□ □□□□□□ **DXM** □□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□ **(□□□□□□, □□□□□□, □□□□□□□□□ □□□□□□□□□): NAC** □□□ □□□□□□□□□ □□□□□□□□□□, □□□ □□□□□□ □□□□□□□□□□□□□□□□□. □□□□□□□□□□□□ □□□□□□ **24–72** □□□□□□□□ □□□ □□□□□□□□□□, □□□□□□□□□ □□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□.

□ □□□□□□□ □□□□□□□□□□□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□ □□□□□□□□□□□□□□□. NAC (□□-□□□□□□□□□ □□□□□□□□□□) □□□□, □□□□□□□□□□□□□□□□ □□□□ □□□□□□□□□□□□□□ □□□□□□ □□□□□ □□□□□□□□□ □□□□□□□ □□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□.

- □□□□□□□ 24 □□□□□□□□□□□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□ □□□□□□□□ DXM □□□□□□□□□□ □□□□□□□□□□□□□□□□□□□, □□□□□□□□□ □□□□ □□□□□□ NAC 600–1200mg □□□□□□. □□□ □□□□□□□□□□□□□□ overdose-□ □□□□□□□□□□□□ □□□□□□□□□□□□□□□□ IV NAC-□□□□□ □□□□ □□□□□□□□□□□□ — □□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□ oral supplementation □□□□□□□□□□□□□□□□□□□□.
- □□□□□□ □□□□□□ □□□□□□□□□□□□□□□ (□□□□□□□□□□□□□ □□□□□□□□□□□□□□□ 24 □□□□□□□□□□□□□□□□□□□ 4 □□□□□□-□ □□□□□□□, □□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□): □□□□□□□□□ □□□□□□□□□□□ □□□□□□. □□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□ □□□□□ NAC (IV NAC) oral □□□□□□□□ □□□□□□□□□□□□. □□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□.
- □□□□□□□□□ □□□□□□□□□□ □□□□□□□□ (AST, ALT, □□□□□□□□□□): □□□□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□ □□-□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□, □□□□□□□□ □□□□ □□□□□□ □□□□□□□□□□□□□□□□□□□□□□ □□□□□ □□□□□□□□□ □□□□□□□□□□□□□□□□.
- □□□□□□□□□□□ □□□□ □□□□□□□□: □□□□□□□□□□□□□□□ □□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□ □□□□□ 4-8 □□□□□□□□□□□□□□□ □□□□□□□□ □□□□□□ (□□□□□□□□□□□ 200–400mg □□□□□□□□□), □□□□□-□□□□□□□□□ □□□□□□ (300mg □□□□□□□□□), NAC (□□□□□□□□□□□ □□□□□□□□□□□□□□□ 600mg).

4.3 — □□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□□□□□

□□□□□□□□□ □□□□□□ □□□□□□□, DXM □□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□:

- NAC (□□□□□□□□ 600–1800mg, □□□□□□□□□□, □□□□□□□□□□□□□□□□□□): □□□□□□□□□□□□ □□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□. NMDA □нта□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□ NAC-□□□□□ □□□□□□□□□□-□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□. □□□□□□ □□□□□□□□□□□□.
- □□□□□□□□□□ □□□□□□□□□□□□□□□ (400–600mg □□□□□□, □□□□□□□□□□ □□□□□□□□□□□□□□□): □□□□□□□□□□□□□□ □□□□□□□□ □□□□□ □□□□□□□□□□□□ □□□□□ □□□□□□□□□ □□ □□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□□□□□□□□.
- □□-□□□□□□□ (200–400mg, □□□□□□□□□□□□□гідно): □□□□□□□□ □□□□□□□□ □□□□□□□□□ □□□□□□□□ □□□□□□□□□; □□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□.
- □□□□□□□□ (□□□□□□□□□□□ 3–5 □□□□□□): □□□□□□□□□□□□□□ □□□□□□□□□□ норма□□□□□□□□ □□□□□□□□ □□□□□□□□ □□□□□□□□ □□-□□□□□□□□□□□□□. □□□□□□□□□□□, □□□□ □□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□ □нта□□□□□□□ □□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□ □□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□.
- □□□□-3 □□□□□ (□□□□□□□□ 2 □□□□□□+): □□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□ □□□□□□□□ □□□□□□□□□; □□□□□□-□□□□□□□□□□□□□□□□□□□□□□□□.

4.4 — □□□□□□□□□ □□□□□□□□□□□□□□

⚠ **3–5 □□□□□□□□□ DXM □□□□□□□□□□ □□□□□□ 5-HTP □□□□□□□□□□□□. □□□□□□□□□□□□□□□□□□□□□□□□, DXM □□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□ □□□□□□□□□ (SERT INHIBITION) □□□□□□ □□□□□□□□□ □□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□ □□□□□□ □□□□□□□□ □□□□□□□□□□□□□ □□□□□□□□□□. □□□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□ □□□□□□□□□.**

- 5-HTP (50–100mg, □□□□□□□□□□□ — □□□□□□□□ □□□□□□ □□□□□ □□□□□□□ □□□□□□□□□□□ □□□□□): DXM-□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□ SERT-□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□□□□□. □□□□□□□□□□□□ SSRI, SNRI, □□□□□□□□□□□□ MAOI □□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□.
- □□-□□□□□□□□□□□□□□□ (500–1000mg, □□□□□□□□□□□□, □□□□□□□□□□□□□ □□□□□□□ □□□□□□□): 5-HTP-□□□□□ □□□□□□ □□□□□□ — □□□□□□□□□□□ □□□□□□□□ □□□□□□□□□□□□, □□□□□□□□ □□□□□□□□. □□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□□□□□.
- □□□□□□□□□□□□ (4–8 □□□□□□, □□□□□□□□□□□□□): □□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□□□□ □□□□□□□□□□□; □□□□□□□□□□□□ □□□□□□□□□□□□□; DXM □□□□□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□

4.5 — [illegible] DXM [illegible] [illegible] HPPD [illegible]

[illegible], [illegible] [illegible] [illegible] DXM [illegible] HPPD [illegible] [illegible] [illegible] [illegible] - [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible] HPPD [illegible]; DXM-[illegible] NMDA, [illegible]-1 [illegible] [illegible] HPPD [illegible] [illegible] [illegible] [illegible].

- DXM [illegible] [illegible]: [illegible] [illegible] [illegible] NMDA, [illegible]-1 [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]. [illegible] [illegible].
- [illegible] [illegible]: [illegible]-[illegible] HPPD-[illegible] [illegible] [illegible] HPPD [illegible] DXM-[illegible] [illegible] [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible].
- [illegible] [illegible] [illegible] 4-[illegible] HPPD [illegible] [illegible] [illegible]: [illegible] [illegible] (EGCG, [illegible]-[illegible] [illegible], NAC, [illegible], DHA), [illegible] [illegible], [illegible] [illegible], [illegible] SSRI [illegible] [illegible] (SSRI [illegible] [illegible]).
- [illegible] [illegible] [illegible], 4 [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]: [illegible]. HPPD [illegible] [illegible] [illegible] [illegible] [illegible].

4.6 — [illegible] [illegible] [illegible]

[illegible] — [illegible] [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible].

[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [

(□□□□□□□□□□□□□□□□□□□□, □□□□□□□□□□□□, □□□□□□□□□□□□□□□) □□□□□□□□□□□□□□□.
□□□□□□□□□□□□□□□ ADHD □□□□□□□□□□□□□□□□ □□□□□ □□□□□□□□□□□□□□□□□□□□

	[illegible]; [illegible] [illegible] [illegible] ([illegible] [illegible]-[illegible] [illegible] [illegible])		[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]-[illegible] [illegible] [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible].
[illegible]	GABA, [illegible] [illegible] [illegible] [illegible]; [illegible]; (б) [illegible] [illegible] [illegible] (вы) [illegible] [illegible] [illegible] [illegible] [illegible].	[illegible] [illegible] 1-8	[illegible] DXM [illegible] (вызывает [illegible] [illegible] [illegible] DXM-[illegible] [illegible]-1, NMDA [illegible] [illegible] [illegible] COMT [illegible]), [illegible] [illegible] [illegible] [illegible] [illegible]. [illegible].
Semax	BDNF [illegible]; [illegible] [illegible]; [illegible] [illegible] — [illegible]-[illegible] [illegible] [illegible] [illegible] [illegible], [illegible] BDNF-[illegible] [illegible] [illegible].	[illegible] [illegible]	DXM [illegible] [illegible] [illegible] - [illegible], [illegible] [illegible] [illegible], [illegible] [illegible] - NMDA [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] ADHD [illegible] [illegible] [illegible]. BDNF-[illegible] [illegible] [illegible] [illegible] [illegible]. [illegible].

[illegible] 5 — [illegible] — [illegible]

[illegible] — [illegible] 10 [illegible] — OTC [illegible]

OTC [illegible] DXM [illegible] [illegible]: [illegible] [illegible] [illegible], [illegible] [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible] [illegible] $8 [illegible] [illegible] 10 [illegible] [illegible].

DXM [illegible]

[illegible]	[illegible] [illegible]	[illegible]
[illegible] [illegible] [illegible] [illegible]	[illegible] [illegible] [illegible] OTC- [illegible]. [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible].	[illegible] [illegible] [illegible] [illegible] [illegible] [illegible]. [illegible]: [illegible] [illegible] & [illegible] [illegible] [illegible] [illegible] [illegible]. [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]. 10 [illegible]: [illegible] [illegible], [illegible] [illegible] [illegible] 10 [illegible] [illegible].
[illegible] [illegible]	DXM [illegible] [illegible] [illegible] [illegible] [illegible]. [illegible] [illegible] [illegible] — [illegible] NMDA [illegible] [illegible] [illegible] [illegible] — [illegible] [illegible], [illegible]	[illegible] [illegible] [illegible]: 5-MTHF, [illegible], [illegible], [illegible] [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

	[illegible] [illegible].	[illegible], [illegible] [illegible] [illegible] [illegible].
[illegible] — [illegible] [illegible]	DXM [illegible] [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] — [illegible] DXM [illegible] [illegible] [illegible] [illegible]. [illegible] [illegible] DXM [illegible].	[illegible] [illegible] [illegible]. [illegible] (DXM) [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] 05 [illegible] [illegible]. [illegible] [illegible] — [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] — [illegible].
[illegible] [illegible] - [illegible] [illegible] (social anxiety)	DXM-[illegible] [illegible]-1 [illegible] [illegible] [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible] — [illegible] [illegible] [illegible] [illegible] DXM-[illegible] [illegible] [illegible].	[illegible] 4-7-8 [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible] [illegible] (social anxiety). [illegible] — [illegible], [illegible], [illegible] [illegible] [illegible].
[illegible] [illegible] / [illegible] [illegible]	DXM-[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible].	[illegible] [illegible] 05 [illegible] [illegible] [illegible]: [illegible] DXM-[illegible] [illegible], [illegible], [illegible]. [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]. [illegible] [illegible]; [illegible] [illegible] [illegible] [illegible] [illegible] [illegible].

DXM [illegible] [illegible] - 5 [illegible] [illegible] [illegible] (10 [illegible])

1. [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible] [illegible]: [illegible] [illegible]. [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible] [illegible]. 10 [illegible] [illegible]: [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] 10 [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible] [illegible].
2. 4-7-8 [illegible] [illegible] - [illegible] [illegible]. [illegible] [illegible] [illegible] OTC [illegible] [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible] [illegible] [illegible].

3. NAC-□□ маг□□□□□□ □□□□□□□□ (□□□□□□□□□□ □□□□□□ □□□□□□□□ □□□□□□□□ □□□□□□□□). □ □□□□□□□□□□□□□ □□□□□□□□□□□□ NMDA, □□□□□□□□□ □□□□□□□□□□. □□□□□□□□□□ □□□ □□□□□□□□□□□ □□□□□ □□□□□; □□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□□ □□□□□□□.
4. □□□□□□□□ □□□□□□□□□ □□□□ □□□□□. □□□□□□□□□? □□□□□□□□□□□? □□□□□/□□□□□□□□□□□? □□□□□□□□□ □□□? □ □□□□□□□□ □□□□□□□□ □□□□□□□□□ □ □□□□□□ □□□□□□□□□□ □□□□□□. □□□□□ □□□□ □□□□□□□□□ □□□□□□□ □□□□□ □□□□□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□□□.
5. □□□□□□□□□ □□□□□□□ □□□□□ □□□□□□□□□□□ □□□□□□□. □□□□□□□□□ □□□□□ □□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□: □□□□□□□ □□□ □□□□□□□□□□□□□□□. □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□. OTC-□□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□ □□□□□□□□□□□ □□□□□□ □□□□□□□ □□□□□□□□□ □□□□□□□□□.
6. □□□□□□□□□□□. □□□□□□□□□ □□□□□□□ □□□□□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□ □□□□□□□□□□ □□□□□□□. □□□□□□□□□ □□□ □□□□□□□□□□□□□□□□□□□ □□□□ □□□□□. □□□□□□□□□□□ □□□□□□□□□□ OTC □□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□□, □□□□□ □□□□□□□□□□□□□□ □□□□□□ □□□□□□□ — □□□□□□□□□, □□□□□□, □□□□□□ — □□□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□. □□□□□□□□□□□□□□□ □ □□□□□□□□□□□□□□ □□□□□□□□□.
7. □□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□/□□□□ □□□□□□ □□□□□□□. □□□□□□ 6: NSDR, □□□□□□□, □□□□□□□□□□□□□ □□□□□□□□□, □□□□□ □□□□□□ □□□□□□□□□ □□□□□□. □□□□□□□ □□□ □□□□□□□□□□□□□□□□□□ — □□□□□□ □□□□□□□□□□□□□□□□□ □□□ □□□ □□□□□□□ □□□□□.

Раздел 6 — Клинические рекомендации: дозирование, взаимодействия, безопасность, DXM

6.1 Дозирование — терапевтические диапазоны, титрование, NSDR-протоколы, клинические соображения — Клинические рекомендации DXM

DXM-ориентированное дозирование требует понимания нескольких взаимосвязанных переменных. Клинические рекомендации должны учитывать:

- Терапевтические диапазоны для различных показаний: различные показания (депрессия, тревожность, ПТСР — DMN дезактивация, нейропластичность, NSDR/йога нидра, когнитивное улучшение) требуют различных подходов к дозированию.
- Протоколы титрования для безопасности: титрование снижает риск побочных эффектов - тошноты, головокружения, дисфории, ощущения слабости, паники.
- Взаимодействия лекарственных препаратов: клинически значимые взаимодействия с SSRI - серотонинергическая токсичность, ингибирование CYP2D6 и CYP3A4, усиление седативных эффектов.
- ADHD клинические соображения: ADHD — уникальная клиническая популяция, требующая специальных подходов, включая потенциальное использование. Клинические соображения включают: дозирование, взаимодействия, безопасность, потенциальное злоупотребление.

Терапевтические диапазоны дозирования DXM

DXM клинический контекст	Терапевтический диапазон	Клинические соображения
Депрессия, тревожность - клинические показания,	Средние (терапевтические дозы); NSDR; когнитивное улучшение	Клинические исследования - обычно 20 миллиграмм. Клинические (терапевтические 04). NSDR: клинически 20–30 миллиграмм, клинически миллиграмм, терапевтическое клинических. Клинические

[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] ([illegible]-1 + SERT)	[illegible]; [illegible] [illegible] [illegible]; [illegible]; [illegible]	[illegible] [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible] [illegible]. [illegible], [illegible]. [illegible] [illegible] [illegible] [illegible] [illegible].	DXM-[illegible] [illegible] [illegible] [illegible]-1, [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible]. [illegible] DXM [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible].
[illegible] [illegible] [illegible]	[illegible] [illegible] [illegible] [illegible]; [illegible]; [illegible] [illegible] [illegible]; [illegible]	[illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

	□□□□□□□□□□); □□□□□□□; □□□□□□□□□□ □□□□□□□□□□; □□□□□□□□□	□□□□□□□□□□□. □□□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□ □□□-□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□ (30–45 □□□□□□□□□). □□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□.	□□□ DXM □□□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□ □□□□□□□□□□□. □□□□□□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□, □□□□□□□□□□□□ □□□□ □□□□□□□□□□□□□□□□□□ DXM □□□□□□□□□□□□ □□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□.

□□□□□□□□□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□□□□□□□

□□□□□□□□□□ — 15 □□□□□□□□ **DXM** □□□□□□□□□□□ □□□□□□□□□□□ **30** □□□□□□□□ □□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□□□□□□

DXM □□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□ □□□□□□□□□□□□□□□□□□□□□□□□ □□□□ □□□□□□□□□□□□□. □ □□□□□□□□□□□□□□□□□□□□□□ □□□□□□□ □□□□□□□□□□ □□□□□□□□□□ □□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□ □□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□□□□□□:

- □□□□□□□ □□□□□□□□□: □□□□□□□□□□□□□□ □□□□□□□□□□ □□□□□□□ □□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□. □□□□□□□□ □□□□ □□□□-□□□□□□□□ □□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□ — DXM □□□□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□ □□□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□□ □□□□ □□□□□□□□ □□□□□□□□□□□□□□□□□□□□

[illegible]) [illegible] [illegible] [illegible]

[illegible] 7 — [illegible] [illegible] [illegible]: [illegible]

[illegible]	[illegible] [illegible]	[illegible] [illegible]	**DXM** [illegible] [illegible]
[illegible] [illegible] [illegible] (CYP2D6 0-7)	[illegible]; [illegible] [illegible] [illegible]; [illegible] [illegible] 0	[illegible] [illegible] [illegible]; NAC [illegible]; HPPD ; [illegible] [illegible] [illegible]	[illegible] [illegible] [illegible]: [illegible] NAC [illegible] [illegible] [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] DXM [illegible]. [illegible] [illegible] [illegible] [illegible]; [illegible] [illegible] [illegible].
[illegible] [illegible] (MTHFR 1-14)	[illegible] [illegible] [illegible] 07, [illegible] [illegible] 09, [illegible] [illegible] 17	[illegible] (SERT + [illegible]), mag[illegible], 5-[illegible], [illegible] [illegible], [illegible], [illegible]). [illegible] 1-[illegible] mag[illegible]. [illegible] 1-[illegible] 5-MTHF. 5-HTP: [illegible] SERT [illegible] [illegible] [illegible] [illegible] [illegible] DXM [illegible] [illegible] [illegible] 3–5 [illegible] [illegible]. [illegible] [illegible] [illegible].	[illegible] 1-[illegible] NAC — [illegible] [illegible] [illegible] [illegible] (NMDA [illegible], [illegible] [illegible] [illegible]). [illegible] 1-[illegible] mag[illegible]. [illegible] 1-[illegible] 5-MTHF. 5-HTP: [illegible] SERT [illegible] [illegible] [illegible] [illegible] [illegible] DXM [illegible] [illegible] [illegible] 3–5 [illegible] [illegible]. [illegible] [illegible] [illegible].
[illegible] [illegible] (CYP2D6 1-4)	CYP2D6 [illegible]; SLC6A4; COMT; MTHFR; DRD4/DAT1	CYP2D6 [illegible] [illegible]; [illegible] [illegible] [illegible]; [illegible] [illegible]	DXM [illegible] [illegible] [illegible] [illegible] [illegible] CYP2D6 — [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]. ADHD [illegible] [illegible] (DRD4, DAT1) ADHD [illegible] [illegible] [illegible] [illegible].
[illegible] [illegible] [illegible] (CYP2D6 2–12)	[illegible] ; [illegible] [illegible] [illegible]; [illegible]; [illegible] 4.6	[illegible] [illegible]; [illegible] [illegible] [illegible]; [illegible] [illegible]; [illegible] [illegible]	DXM-[illegible] [illegible] [illegible] [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

			□□□□□□□□□□□□□□□□□□□□. □ □□□□□□□□□ □□□□□□□□□□□□, □□□□□□□□□□ □□□□□□□□ □□□□□□□□□ □□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□.
□□□□□□□□□□□□□□ □□□□□□□□□□□□□ □□ (□□□□□□□ 1-8 □□□□□□□□□□□□)	□ □□□□□□□□□□ □□□□□ 4.5; □□□□□□□□□□□□□□□ □□□□ □□□□□□□	□□□□□□□□ □□□□□□□□; □□□□□□□□□□□□; □□□□□□□; □□□□□□□□ □□□□□□□□□□□□□□□	DXM-□□□□ □□□□□□□□□□□□ HPPD □□□□□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□□□□ HPPD □□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□, □□□ □□□□□□□□ □□□□□□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□. □□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□ □□□□□□□ □□□□□ □□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□. □□□□□□□□ □□□□□□□□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□□□□□□□□ □□□□□ □□□□□□□□□□□.
□□□□□□□□□ □□□□□□□ □□□□□□□□□□□□□ □ (□□□□□ 1-6)	□□□□□□□□□□□□□ □□□□ 04 (□□□□□□□□), □□□□□□□□□□□□□ □□□□ 03 (□□□□□□□□□□), □ □□□□□□□□□□ □□□□□ 6	□□□□□□□□ □□□□□□□/NSDR; □□□□□□□□□; □□□□□□; DXM □□□□□□□□□□□□□□□□□□□□

□□□□□□ 8 — □□□□□□□□□□ □□□□□□□□□□: □□□□□□□□□□ □□□□□□□

DXM □□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□□□□□ систематиче□□□□□ □□□□□□□□ □□□□□□ □□□□□□□□□□ □□□ □□□□□□□□, □□□□□□□□ □□□□□□□□ □□□□□ □□□□□: □□□ □□□□□□□□□□□□□□□□□, □□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□, □□□□□□□ □□□□□ □□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□□□ □□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□. DXM-□□ MAT (Medication Assisted Treatment) □□□□. DXM-□□□□□□□□□□□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□. □□□□□□□□□ □□□□□□□□□□□□□□□□□ пе□□□□□□□□□□□ □□□□□□□ □□□□□□□□ □□□□□□□□ □□□□□□□□ DXM □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□□□□.

□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□: □□□□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□ □□□□□□□□□□□□ □□□□□□□ □□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□□□□. □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□ 13 (□□□□□□□□□□□□□□□□□ □□□□□□□□□) □□□□□□□□□ □□□□□□□□□□.

8.1 — □□□□□□□□ □□□□□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□

- □□□□□□ □□□□□□□□□□□□□□□ □□□□□□ □□□□□□□□□□□□□□□□□□□ □□□□ □□□□□□□□□□□□: AST, ALT, □□□□□□□□□□, GGT. □□□□□□□□□ □□□□□□□ 3 □□□□□□□□ □□□□□-□□□□□□□. □□□□□□ □□□□□□□□□ □□□□□□□□□□□□; □□□□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□ □□□□□□□□□□□.
- CYP2D6 □□□□□□□□: DXM □□□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□□□□□□□ □□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□. □□□□□□□, □□□□□□□□□□□□ CYP2D6-□□□□□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□ □□□□□□□□□ □□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□ □□□□ □□□□□□□□□□□□□□□□□□□□□□□□.
- ADHD □□□□□□□□□□□□□: ADHD □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□□ □□□□□□□□□□□□□. □□□□ □□□□ □□□□□□□□□ □□□□□□□□□□□ □□□□□ □□□□□□□□ □□□□□□□□□□□□□ - □□□□□□□□□□□□□□□□□□□□□□□□□□ ADHD □□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□.
- □□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□: □□□□□□□□□□□□□-9, □□□□□□-7 □□□□□□□□□□□□□ □□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□ □□□□□□□□□. □□□□□□□□□ □□□□□□□□□□□□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□□□□□□□□ □□□□ □□□ □□□□□□□□□□□□□ □□□□□□□ □□□□□□□□□□□□□.
- HPPD □□□□□□□□□□□□□: □□□□□□□□□□□ □□□□□□□□□ 4+ □□□□□□□□□□□ □□□□□□ □□□□□□□□□□□ □□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□

8.2 — [illegible]

DXM [illegible] [illegible] [illegible], [illegible] [illegible]. '[illegible] [illegible] [illegible]' [illegible] [illegible] [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible] [illegible]:

[illegible] [illegible] [illegible] [illegible] [illegible]orphan (DXM) [illegible] [illegible] — [illegible] [illegible] [X] mg [illegible], [[illegible]]. [illegible] [[illegible] [illegible]: NMDA [illegible] [illegible] / [illegible] [illegible] [illegible] / [illegible] [illegible] / [illegible] [illegible]] [illegible] [illegible]. [illegible] [illegible]-[illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible]. [illegible] фарма[illegible] [illegible] [illegible] CYP2D6 [illegible] [illegible]. [illegible], [illegible] [illegible] [illegible]-[illegible] ADHD/[illegible]/[illegible] [illegible] [illegible] [illegible] [illegible] [illegible].

[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible].

[illegible] — [illegible] [illegible] [illegible] [illegible]

- DXM [illegible]: [illegible] DXM [illegible] [illegible] (18+) [illegible]. [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]. CVS [illegible] DXM [illegible] [illegible] [illegible] [illegible] [illegible]. [illegible] [illegible] — [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible].
- DXM [illegible] [illegible]: Erowid-[illegible] DXM [illegible] (erowid.org/chemicals/dxm) [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]. [illegible] [illegible] [illegible] DXM FAQ [illegible].
- SAMHSA's Treatment Locator (findtreatment.gov): while DXM is rarely listed as a primary substance, substance use disorder treatment for comorbid depression, ADHD, and anxiety is appropriately addressed through the standard treatment locator.
- [illegible]: 1-800-852-8336 ([illegible]) — [illegible] [illegible] [illegible] [illegible] [illegible] [illegible].
- [illegible]: 741741 [illegible] HOME [illegible]

[illegible]

[illegible] — [illegible]

DXM [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible]. [illegible] [illegible]; [illegible] [illegible] [illegible] [illegible]—[illegible] [illegible], [illegible] [illegible] ADHD-[illegible] [illegible], [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible].

[illegible]-37 [illegible] [illegible]: [illegible] [illegible] [illegible]. [illegible] [illegible] DXM [illegible], [illegible] [illegible] [illegible]. [illegible] NMDA [illegible], [illegible] [illegible]-1 [illegible], [illegible] [illegible] [illegible] — [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible].

DXM [illegible] OTC [illegible] [illegible] [illegible]. [illegible] $8 [illegible] [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible], [illegible], [illegible] [illegible] [illegible] [illegible].

[illegible] [illegible]. [illegible] MTHFR-[illegible] [illegible] [illegible] SSRI-[illegible] [illegible] 5-MTHF [illegible]. ADHD [illegible] DXM [illegible] [illegible]-1 [illegible] фарма[illegible] [illegible] [illegible] قال[illegible], [illegible] DXM [illegible] [illegible]. NMDA [illegible].

[illegible] [illegible] [illegible]: [illegible] [illegible] [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible] [illegible].

DXM [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible].

— — —

DXM □□□ □□□□□□□: erowid.org/chemicals/dxm | □□□ □□□: 1-800-852-8336 | □□□□□□□□□
□□□□□□□□□□: HOME □□□□□ 741741 □□□□□□ □□□□□□□

□□□□□ □□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□ □□□□□ □□□□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□ □□□□□.

Crisis: call or text 988 | Emergency: 911 | SAMHSA: 1-800-662-4357

⚠ □□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□ □□□□□ — □□□□□□□□□□□□ □□□□

Recovery Kernel □□□□□□□□□□ DXM-□ □□□□□□ □□□□□□ □□□□□□□ | □□□□□□□□ □□□□□□□□ □□□□□□□□ □□□□□□